Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Boardman

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
The Lancet. Diabetes & Endocrinology|April 16, 2014
Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trialMichaela Diamant, Luc Van Gaal, Bruno Guerci, et al.
Journal of Diabetes Investigation|May 21, 2014
Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitusLinong Ji, Yukiko Onishi, Chul Woo Ahn, et al.
Diabetes Care|January 3, 2012
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind studyDavid Russell-Jones, Robert M Cuddihy, Markolf Hanefeld, et al.
International Journal of Neonatal Screening|February 23, 2024
Stakeholder Views of the Proposed Introduction of Next Generation Sequencing into the Cystic Fibrosis Screening Protocol in EnglandPru Holder, Corinna C Clark, Louise Moody, et al.
International Journal of Neonatal Screening|April 23, 2024
International Perspectives of Extended Genetic Sequencing When Used as Part of Newborn Screening to Identify Cystic FibrosisCorinna C A Clark, Pru Holder, Felicity K Boardman, et al.
Clinical Epidemiology|December 26, 2017
Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomesJason C Simeone, Jay P Bae, Byron J Hoogwerf, et al.
Analytical Chemistry|July 19, 2016
Rapid Detection of Bacteria from Blood with Surface-Enhanced Raman SpectroscopyAnna K Boardman, Winnie S Wong, W Ranjith Premasiri, et al.
European Journal of Medical Genetics|October 2, 2020
Which types of conditions should be included in reproductive genetic carrier screening? Views of parents of children with a genetic conditionLauren A Thomas, Sharon Lewis, John Massie, et al.
Lancet (London, England)|November 13, 2012
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyJohn B Buse, Michael Nauck, Thomas Forst, et al.
Diabetologia|May 1, 2026
Psychosocial implications, acceptability and ethics of screening for paediatric type 1 diabetes: a systematic review and mixed methods evidence synthesisLauren M Quinn, David Stanley, Francesca Milano, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
The Lancet. Diabetes & Endocrinology|April 16, 2014
Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trialMichaela Diamant, Luc Van Gaal, Bruno Guerci, et al.
Journal of Diabetes Investigation|May 21, 2014
Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitusLinong Ji, Yukiko Onishi, Chul Woo Ahn, et al.
Diabetes Care|January 3, 2012
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind studyDavid Russell-Jones, Robert M Cuddihy, Markolf Hanefeld, et al.
International Journal of Neonatal Screening|February 23, 2024
Stakeholder Views of the Proposed Introduction of Next Generation Sequencing into the Cystic Fibrosis Screening Protocol in EnglandPru Holder, Corinna C Clark, Louise Moody, et al.
International Journal of Neonatal Screening|April 23, 2024
International Perspectives of Extended Genetic Sequencing When Used as Part of Newborn Screening to Identify Cystic FibrosisCorinna C A Clark, Pru Holder, Felicity K Boardman, et al.
Clinical Epidemiology|December 26, 2017
Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomesJason C Simeone, Jay P Bae, Byron J Hoogwerf, et al.
Analytical Chemistry|July 19, 2016
Rapid Detection of Bacteria from Blood with Surface-Enhanced Raman SpectroscopyAnna K Boardman, Winnie S Wong, W Ranjith Premasiri, et al.
European Journal of Medical Genetics|October 2, 2020
Which types of conditions should be included in reproductive genetic carrier screening? Views of parents of children with a genetic conditionLauren A Thomas, Sharon Lewis, John Massie, et al.
Lancet (London, England)|November 13, 2012
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyJohn B Buse, Michael Nauck, Thomas Forst, et al.
Diabetologia|May 1, 2026
Psychosocial implications, acceptability and ethics of screening for paediatric type 1 diabetes: a systematic review and mixed methods evidence synthesisLauren M Quinn, David Stanley, Francesca Milano, et al.
Pageof 9